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Abstract
Background: Vasomotor symptoms such as hot flashes and night sweats are a common concern of perimenopausal and
postmenopausal women and are associated with a decreased quality of life. These symptoms can be effectively managed
with hormone therapy, but safety concerns limit its use. Thus, understanding the effectiveness of nonpharmacologic
therapies such as acupuncture or yoga is critical to managing these common symptoms in older women. Our review
seeks to address the following question: In women with menopause-associated vasomotor symptoms, what are the
effects on health-related quality of life, vasomotor symptoms, and adverse events of the following nonpharmacologic,
nonherbal interventions as compared with any inactive control or active comparator: (a) acupuncture, (b) yoga, tai chi, and
qigong, (c) structured exercise, and (d) meditation, mindfulness-based practices, and relaxation?
Methods: We describe a protocol for an umbrella review approach, supplemented by evaluating randomized controlled
trials (RCTs) published after the most recent good-quality systematic review for each of the eligible interventions. Specific
interventions were chosen based on current literature and with input from a technical expert panel and organizational
stakeholders. We will conduct a thorough literature search and perform a quality assessment of potentially included
systematic reviews and RCTs.
Discussion: Our umbrella review, supplemented by an additional search for eligible RCTs, aims to synthesize existing
evidence on the use of nonpharmacologic, nonherbal interventions to manage bothersome vasomotor symptoms in
perimenopausal and postmenopausal women.
Systematic review registration: PROSPERO CRD42016029335
Keywords: Vasomotor symptoms, Menopause, Nonpharmacologic therapy, Umbrella review
Background
Hot flashes and night sweats (vasomotor symptoms or
VMS) are two of the most common symptoms reported
by perimenopausal and postmenopausal women and are
experienced by as many as 80 % of women [1]. The
mean age at VMS onset is 51 years, and frequent VMS
can last more than 7 years [2], leading to increased
healthcare encounters for symptom relief [3] and reduc-
tions in quality of life (QOL) [4, 5]. The impact of VMS
on QOL can be worse for certain populations of women
such as those who undergo surgical rather than natural
menopause [6]. Moreover, the degree to which VMS are
bothersome is determined not only by how frequently
the symptoms occur but also by other factors such as
duration of VMS and coexistent sleep problems [7].
Hormone therapy is an effective treatment for reducing
VMS but is recommended only for short-term use due
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to substantial risks, such as cardiovascular events and
uterine and breast cancers [8, 9]. Also, some women are
not candidates for hormone therapy because of comor-
bid health conditions such as liver disease or a history of
blood clots. This situation leaves women with VMS in
need of nonhormonal treatment options for many years.
For this reason, the identification of safe and effective
nonhormonal strategies is needed.
Many perimenopausal and postmenopausal women are
already using nonpharmacologic agents to manage VMS
[10–12]. Nonpharmacologic treatments for VMS include
herbal remedies (e.g., black cohosh), mind and body prac-
tices (e.g., yoga, tai chi), structured exercise programs, and
complementary and alternative medicine interventions
(e.g., acupuncture) [13]. A 2015 Agency for Healthcare
Research and Quality (AHRQ) systematic review [14] ex-
amined the comparative effectiveness of estrogens, isofla-
vones, selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs),
gabapentin, black cohosh, and ginseng for menopausal
symptoms, including VMS. However, the AHRQ review
did not address nonpharmacologic, nonherbal interven-
tions such as mind and body practices, structured exercise
programs, or complementary and alternative medicine in-
terventions. Also in 2015, the North America Menopause
Society released a position statement providing recom-
mendations for many such intervention types and graded
the level of evidence for their recommendations; however,
this was not a formal systematic review of the literature
and included a discussion of both herbal and other non-
hormonal pharmacologic treatments [15].
Because nonpharmacologic treatments are conceptu-
ally attractive to treat menopause-associated VMS, we
will evaluate evidence from systematic reviews (SRs) and
randomized controlled trials (RCTs) on selected non-
pharmacologic, nonherbal therapies. Our objective with
this review is to summarize and update the evidence
from SRs and recent RCTs on selected nonpharmacolo-
gic and nonherbal approaches for the management of
menopause-associated VMS. Specifically, we seek to an-
swer the following key question: In women with VMS
that are associated with perimenopause or postmeno-
pause, what are the effects on health-related quality of
life, VMS, and adverse events of the following nonphar-
macologic, nonherbal interventions as compared with
any inactive control or active comparator: (1) acupunc-
ture, (2) yoga, tai chi, and qigong, (3) structured exer-
cise, and (4) meditation, mindfulness-based practices,
and relaxation?
Methods/design
This protocol has been registered in the PROSPERO data-
base for systematic reviews, a web-based international
registry of systematic review protocols (#CRD42016029335)
[16]. A PRISMA-P checklist was completed for this proto-
col (Additional file 1).
Given the multiple high-quality SRs in this topic area,
we decided to use a method commonly known as an um-
brella review or a review of reviews. Additionally, we will
supplement this approach by searching for and evaluating
RCTs published after the most recent good-quality SR for
each of the eligible interventions. We will follow meth-
odological guidance from the Cochrane Collaboration [17]
and AHRQ’s Evidence-based Practice Centers [18].
Selection of nonpharmacologic interventions
Numerous interventions could be considered nonpharma-
cologic treatments for VMS in perimenopausal and meno-
pausal women, particularly variations of complementary
and alternative medicine approaches to symptom control
[10]. To focus the selection of interventions for this review,
we invited individuals with expertise in the field of meno-
pause management both from within the Veterans Health
Administration (VHA) and outside the VHA to participate
in a technical expert panel. This panel provided consult-
ation during the process of reviewing and organizing a list
of potential interventions originally generated by the pri-
mary review team based on published literature and clinical
practice. Final selection of interventions for review (Table 1)
was chosen based on priorities from VHA stakeholders
who proposed and supported this review. Of note, we ac-
knowledge that some included interventions (e.g., yoga)
could potentially fit in multiple categories (e.g., structured
exercise, meditation) and that some interventions are often
delivered together in practice. As our understanding of the
literature develops, we may add or change intervention cat-
egories as appropriate. To enable our ability to identify
meaningful and specific intervention treatment effects, eli-
gible interventions that are part of a multimodal interven-
tion will be included only if it is possible to isolate the
effect of the eligible intervention. If multimodal interven-
tions are included in relevant SRs, we will prioritize results
that isolate the effects of the eligible intervention.
Eligible SRs and RCTs
We will include SRs and RCTs that evaluate an eligible
intervention for bothersome VMS associated with peri-
menopause or postmenopause. Perimenopause is defined
as amenorrhea for greater than 60 days in the past
12 months; postmenopause is defined as being without a
menstrual cycle due to spontaneous or surgical reasons
for the preceding 12 months [19, 20]. For the SRs, we
will accept the definition of VMS as used by the authors
and will track any variations in what was used. For
RCTs, we will consider bothersome VMS defined as any
of the following: self-identified “bothersome” hot flashes,
moderate to severe vasomotor symptoms as defined by
the FDA [21], hot flashes that occur at least 6 days in
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the previous 2 weeks [2], or hot flashes that are associ-
ated with functional impairment (e.g., impairment in
role, social, emotional, or physical functioning). Women
with breast cancer will be included. Eligible interven-
tions are listed in Table 1. Specifically, we will include
interventions that fall under four main categories: acu-
puncture, acupressure; yoga, tai chi, qigong; structured
physical activity; and meditation, mindfulness, relax-
ation. Because the interventions in each of these categor-
ies have multiple subtypes, we have listed those that we
believe will be relevant to the objective of this review
based on current literature and expert opinion.
Additionally, we have provided definitions for the inter-
vention types of interest to further guide inclusion (e.g.,
structured exercise). Any inactive control (e.g., waitlist,
attention control, sham acupuncture, information con-
trol, or unenhanced usual care) or active comparator
(e.g., hormone treatments, antidepressants, dietary sup-
plements, health education, unstructured forms of exer-
cise) will be allowed. SRs that include mixed settings
that are inclusive of outpatient/community settings will
be eligible, but we will prioritize results from outpatient/
community settings. If it is impossible to disaggregate
results, we will describe the number of studies/patients
contributed by studies conducted in outpatient/commu-
nity settings. For SRs, we will accept the timing of
outcome assessments as specified by the review. For
RCTs, outcomes must be assessed ≥60 days after treat-
ment assignment in order to provide findings based on a
reasonably long duration of follow-up given the chron-
icity of VMS; the choice of this duration cutoff was vet-
ted with our technical expert panel. Additionally for
inclusion, SRs and RCTs must include at least one of
our primary or secondary outcomes of interest as de-
scribed in the following section.
We define SRs as studies that include an explicit
search, prespecified eligibility criteria, an evaluation of
the quality of included studies or risk of bias, and a syn-
thesis or an attempt to synthesize findings quantitatively
and/or qualitatively [22]. We will exclude SRs that re-
view complementary and alternative therapies in general
without a specific focus on an intervention of interest.
We will also exclude SRs that are found to be of poor
quality after quality assessment is completed (see “As-
sessment of methodological quality of SRs” section
below). RCTs will not be excluded due to quality limita-
tions, but we will make interpretations that incorporate
our risk of bias assessment.
Review outcomes
We have two primary outcomes for this study: (1) over-
all and condition-specific health-related quality of life
Table 1 Eligible interventions and definitions
Intervention category Definitions and examples
Acupuncture, acupressure Acupuncture from any tradition will be considered, including auricular acupuncture, electroacupuncture,
acupressure, and laser acupuncture.We will exclude studies where acupuncture was administered
in conjunction with Chinese herbal therapies. Cupping therapy will be excluded unless it is simply
a component of an acupuncture intervention.
Yoga, tai chi, qigong (as defined by
study investigators)
Yoga is generally defined as physical exercises and bodily positions or postures, breathing control
practices, and meditation.
Tai chi is generally defined as series of movements performed in a slow, focused manner accompanied
by deep breathing.
Qigong is generally defined as system of coordinated body posture and movement, breathing, and
meditation.
Meditation, mindfulness, relaxation Practices include:
• Mindfulness-based stress reduction
• Progressive relaxation
• Bernstein and Borkovec’s progressive relaxation
• Everly and Rosenfeld’s passive relaxation
• Madder’s applied relaxation
• Poppen’s behavioral relaxation training
• Mitchell method
• Alexander technique
• Benson’s relaxation response
• Guided imagery-based approaches
• Roll breathing
• Paced respiration
• 4-7-8 breathing technique
• Hypnosis
• Other approaches that focus on diaphragmatic breathing
Structured exercise, physical activity Defined as physical activity that is regular and done with the intention of improving or maintaining
physical fitness or health or performed as part of a class or with support from a health professional.
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(HRQOL) and (2) frequency and intensity of VMS.
HRQOL was chosen as one of the primary outcomes for
this study because it constitutes a global measure of the
impact of VMS on an individual’s well-being and be-
cause of the interest of our VHA stakeholders and exist-
ing evidence that women Veterans may experience
greater adverse effects on QOL from VMS than non-
Veteran women [23]. We will assess this outcome based
on the measures available from included studies and re-
views that may be specific to the menopausal condition
(e.g., a menopause rating scale [6] or the Women’s
Health Questionnaire [24]) or more general. Secondary
outcomes include psychological well-being (i.e., depres-
sive or anxiety symptoms), sleep quality, and adverse ef-
fects. For SRs, we will accept the timing of outcome
assessments as specified by the review. For eligible RCTs
that are published subsequent to the relevant SR, out-
comes must be assessed greater than 60 days after treat-
ment assignment for reasons stated above. We will
prioritize validated scales over unvalidated scales or
single-symptom measures (e.g., frequency of hot flashes).
We also plan to collect information about serious ad-
verse effects [25].
Literature search methods
We will conduct a search of electronic databases using
MeSH keywords and selected free-text terms for the in-
terventions and health conditions of interest as well as
terms for SRs and RCTs (Table 2). To ensure complete-
ness, search strategies (Table 3) will be developed in
consultation with a master librarian. The search for SRs
will be conducted in PubMed and the Cochrane
Database of Systematic Reviews. If we identify no SRs
for any of the included interventions, we will search
PROSPERO (a database of review protocols) [26] for
submitted protocols related to the specified health con-
ditions and which may become available to summarize a
topic area in the near future. We will include moderate-
and high-quality SRs published from January 1, 2010 for-
ward, which will enable us to identify reviews that likely
are still current since the median time needed for updat-
ing an SR is 5.5 years [14]. Because Cochrane reviews
are updated every 2 years and may be published in both
the Cochrane database and peer-reviewed journals, we
may encounter more than one review published by the
same author on the same topic. In this case, we will in-
clude only the most recent and fully reported review.
We will include only full journal articles (i.e., not ab-
stracts or dissertations). Only English language publica-
tions will be included.
Subsequent to the identification of SRs, we will con-
duct a search for additional individual RCTs published
after the search date noted in the SR for each interven-
tion category. The search for RCTs will be conducted in
PubMed, EMBASE, CINAHL, and the Allied and Com-
plementary Medicine Database (AMED). However, if we
cannot find any recent SRs on a particular intervention,
we will simply report this finding and not try to identify
and conduct a de novo synthesis of all primary studies.
As with SRs, only English language publications and full
journal articles will be included for RCTs.
Using prespecified inclusion/exclusion criteria, titles
and abstracts of SRs and RCTs identified through our
primary search will be reviewed by two reviewers for
Table 2 Search concepts and keywords
Concept MeSH terms Title/abstract keywords
Menopause Menopause; Climacteric; Hot Flashes Menopaus*; Peri-menopaus*; Postmenopaus*;
Climacteric*; Hot flash*; Hot flush*;
Night sweat*; Vasomotor symptom*
Systematic review – Systematic; Systematic Review;
Umbrella Review; Meta-analysis
Acupuncture Acupuncture therapy; Acupuncture; Acupressure Acupuncture; acupressure;
electroacupuncture
Mind-body therapies Mind-body therapies; Breathing exercises; Imagery
(psychotherapy); Meditation; Relaxation therapy;
Mind-body relations, metaphysical; Mindfulness,
Hypnosis
Mind-body therap*; Mind body medicine;
Breathing exercise*; Respiratory muscle
training; Guided imagery; Meditation;
Relaxation therapy; Relaxation technique*;
Alexander technique; Mindfulness-based
stress reduction; MBSR; Paced respiration;
Alternative medicine, Hypnosis
Yoga, tai chi; qigong Yoga; Tai Ji Yoga; Tai Ji; Tai Chi; T'ai Chi; Taiji; Taijiquan;
Qi Gong; Qigong; Ch'l Kung; Chi Kung;
Kinesiotherapy
Exercise Exercise; Circuit-based exercise; Muscle stretching
exercises; physical conditioning human; Resistance
training; Running; jogging; Swimming; Walking;
Exercise movement techniques; Sports
Exercise*; Resistance training; Physical
activity; Aerobic activity; Sport
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potential relevance to the key question. Articles included
by either reviewer will undergo full-text screening. At
the full-text screening stage, two independent reviewers
must agree on a final inclusion/exclusion decision and
the rationale for this decision. Articles meeting eligibility
criteria will be included for data abstraction. All results
will be tracked in both DistillerSR, a web-based data
synthesis software program (Evidence Partners Inc.,
Manotick, ON, Canada), and EndNote® reference man-
agement software (Thomson Reuters).
Assessment of methodological quality of SRs
We will evaluate the quality of SRs in the following
manner: the reviewer assigned to abstract the article will
perform an initial assessment, which will then be over-
read by a second reviewer. Disagreements will be re-
solved between the two reviewers or when needed by
arbitration from a third reviewer.
We will use the following key quality criteria for SRs,
adapted from ROBIS [27] and AMSTAR [28]: search
methods adequate for replication and comprehensive, se-
lection bias avoided, data abstracted reliably, characteris-
tics of primary literature reported and quality assessed
appropriately, results synthesized using appropriate
methods, publication bias assessed, conflict of inter-
est reported, and conclusions supported by results
(Additional file 2). Based on these criteria, SRs will
be categorized as good, fair, or poor quality. Good- and
fair-quality SRs should provide sufficient information to as-
sess the strength of the body of evidence using the GRADE
criteria [29], which includes the major domains of risk of
bias, directness, consistency, precision, and reporting bias.
Poor-quality SRs will be excluded from our review.
For newly identified RCTs, we will use the Cochrane
Collaboration’s risk of bias (ROB) tool [30], which cate-
gorizes biases by six domains (selection bias, perform-
ance bias, detection bias, attrition bias, reporting bias,
and other bias) and makes a summary assessment. For
each item, a summary rating (high, low, or unclear ROB)
is assigned along with a succinct free-text description to
support the rating.
Data collection and extraction
Data from published fair- or good-quality reviews and
newly identified RCTs will be abstracted into a customized
database by one reviewer and overread by a second
Table 3 Search strategy. Database: PubMed (all database searches use the same search strategy). Search date: November 9, 2015
Search Query Items
found
#1 Search "Menopause"[Mesh] OR menopaus*[tiab] OR "Climacteric"[Mesh:NoExp] OR "Hot Flashes"[Mesh] OR peri-menopaus*[tiab]
OR perimenopaus*[tiab] OR postmenopaus*[tiab] OR post-menopaus*[tiab] OR climacteric*[tiab] OR hot-flash*[tiab] OR hot
flash*[tiab] OR hot-flush*[tiab] OR hot flush*[tiab] OR night sweat*[tiab] OR vasomotor symptom*[tiab]
91,908
#2 Search systematic[sb] OR "Systematic Review"[tiab] OR "Umbrella Review"[tiab] OR meta-analysis[tiab] OR "meta analysis"[tiab] 280,172
#3 Search #1 AND #2 2771
#4 Search "Acupuncture Therapy"[Mesh] OR "Acupuncture"[Mesh] OR "Acupressure"[Mesh] OR "acupuncture"[tiab] OR
"acupressure"[tiab] OR "electroacupuncture"[tiab]
23,260
#5 Search #3 AND #4 45
#6 Search "Mind-Body Therapies"[Mesh: NoExp] OR "Mind-Body Therapy"[tiab] OR "Mind Body Therapy"[tiab] OR "Mind-Body
Therapies"[tiab] OR "Mind Body Therapies"[tiab] OR "Mind Body Medicine"[tiab] OR "Breathing Exercises"[Mesh] OR "Breathing
Exercise"[tiab] OR "Breathing Exercises"[tiab] OR "Respiratory Muscle Training"[tiab] OR "Imagery (Psychotherapy)"[Mesh] OR
"Guided Imagery"[tiab] OR "Meditation"[Mesh] OR "Meditation"[tiab] OR "Relaxation Therapy"[Mesh] OR "Relaxation Therapy"[tiab]
OR "Relaxation Techniques"[tiab] OR "Relaxation Technique"[tiab] OR "Alexander Technique"[tiab] OR "Mind-Body Relations,
Metaphysical"[Mesh] OR "Mindfulness"[Mesh] OR "Mindfulness-based Stress Reduction"[tiab] OR "MBSR"[tiab] OR "paced
respiration"[tiab] OR "Hypnosis"[Mesh] OR "Hypnosis"[tiab] OR "Hynotism"[tiab] OR "Hypnotherapy"[tiab] OR "Hynotherapies"[tiab]
OR "Mesmerism"[tiab]
16,823
#7 Search #3 AND #6 16
#8 Search "Yoga"[Mesh] OR "Yoga"[tiab] OR "Tai Ji"[Mesh] OR "Tai Ji"[tiab] OR "Tai-ji"[tiab] OR "Tai Chi"[tiab] OR "T'ai Chi"[tiab] OR
"Taiji"[tiab] OR "Taijiquan"[tiab] OR "Qi Gong"[tiab] OR "Qigong"[tiab] OR "Ch'I Kung"[tiab]
4440
#9 Search #3 AND #8 22
#10 Search "Exercise"[Mesh:NoExp] OR "Exercise"[Majr] OR "Circuit-Based Exercise"[Mesh] OR "Muscle Stretching Exercises"[Mesh] OR
"Physical Conditioning, Human"[Mesh] OR "Resistance Training"[Mesh] OR "Resistance Training"[tiab] OR "Running"[Mesh] OR
"Jogging"[Mesh] OR "Swimming"[Mesh] OR "Walking"[Mesh] OR "Exercise"[tiab] OR "Exercises"[tiab] OR "physical activity"[tiab] OR
"aerobic activity"[tiab] OR "Exercise Movement Techniques"[Mesh] OR "Sports"[Mesh]
378,950
#11 Search #3 AND #10 204
#12 Search #5 OR #7 OR #9 OR #11 247
#13 Search (#12) AND ("2009/01/01"[Date – Publication] : "3000"[Date – Publication]) 132
#14 Search #13 AND "English"[lang] 123
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reviewer. The data abstraction form will be agreed
upon and piloted by all study team members in ad-
vance of full data extraction. Disagreements will be
resolved by consensus or by obtaining a third re-
viewer’s opinion when consensus cannot be reached.
Data elements abstracted will include descriptors to
characterize the type of study, study population (including
number participants, mean age, race/ethnicity, clinical indi-
cation, baseline severity), intervention (including dose and
how delivered), comparator, outcomes reported (including
prespecified subgroup analyses), study quality, moderator
effect or meta-regression analyses, and author conclusions.
In particular, we will collect the following information im-
portant to the occurrence of VMS: the specific definition of
perimenopause used by authors, inclusion of patients with
a history of breast cancer and/or those receiving any
chemotherapeutic agents, and inclusion or exclusion of
women who underwent surgical menopause. Description of
study populations will be taken as reported in the SRs and
will be verified in the original RCTs only if there is concern
for accuracy.
Data synthesis
We will illustrate the article flow and number of in-
cluded studies in a literature flow diagram (Fig. 1). We
will group the SRs and RCTs by intervention.
Data synthesis from SRs
We will prioritize SRs that are the highest quality, most
current, and most relevant to the study question [22].
Relevance will be assessed using the PICOTS (population,
intervention, comparator, outcome, timing, setting) frame-
work along with the search date, review methods, and
completeness of reporting. For each intervention, we will
provide tables or graphical displays to describe the studies
included, study quality, and treatment effects. If inform-
ative, we will display a treatment network, describing the
number and types of interventions evaluated. We will re-
port intervention effects separately for inactive and active
comparators and plan to describe effects using a “forest
top plot” [17] and in table form. We will examine SRs for
relevant subgroup analyses, including concurrent use of
hormone replacement therapy, effects in women with and
without breast cancer, perimenopausal and postmeno-
pausal women, and women with surgical versus natural
menopause. If multiple high-quality, relevant reviews are
included on a single intervention, we will provide a matrix
comparing which studies were included in the reviews.
Data synthesis from RCTs
Although umbrella reviews do not typically search for new
primary studies, our review incorporates this step in order
to identify important new data. Provided the volume of
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Fig. 1 Literature flow diagram
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incorporate these studies into our assessment. We will
search the bibliographies of all the SRs and compare the
results of the RCTs with the conclusions drawn by the
SRs. We will also clearly identify data derived from exist-
ing SRs and data abstracted from newly identified RCTs as
part of this umbrella review.
Meta-analysis
Newly identified RCTs will be summarized qualitatively
and, if indicated, quantitatively (i.e., meta-analysis). How-
ever, no clear rules exist for when a new quantitative syn-
thesis needs to be conducted. We will consider the number
of new studies, the sample size, and the strength of evi-
dence domains [29] as a framework for determining
whether a new quantitative synthesis is indicated. If new
primary studies are likely to change the judgments about
the strength of evidence, we will conduct an updated meta-
analysis. If the new studies are consistent with prior synthe-
ses and likely will not change the conclusion of the review,
then we will not complete an updated meta-analysis.
Narrative summary
In addition, we will narratively describe the major find-
ings and conclusions from the existing reviews. We will
identify evidence gaps by documenting clinical indica-
tions for which there is conflicting evidence across iden-
tified reviews or where reviews concluded that the
existing evidence base is insufficient to reach firm con-
clusions. We also will document topic areas for which
SRs exist but which did not identify relevant RCTs.
Subgroup analysis
When possible, we plan to extract data from eligible SRs to
perform subgroup analysis and further clarify the relation-
ship with specific interventions and VMS. Specific sub-
groups of interest include women with a history of breast
cancer and women with a history of surgical menopause.
Grading the evidence
The strength of evidence for the key question will be
assessed using the approach described in AHRQ’s Methods
Guide for Effectiveness and Comparative Effectiveness Re-
views [18]. In brief, this approach requires assessment of
four domains: risk of bias, consistency, directness, and pre-
cision. Additional domains are to be used when appropri-
ate, including coherence, dose-response association, impact
of plausible residual confounders, strength of association
(magnitude of effect), and publication bias. These domains
will be considered qualitatively, and a summary rating will
be assigned after discussion by two reviewers as high,
moderate, or low strength of evidence. In some cases, high,
moderate, or low ratings will be impossible or imprudent to
make. In these situations, a grade of insufficient will be
assigned.
Discussion
Our review is designed as an umbrella review supple-
mented by an additional search for eligible RCTs pub-
lished after the relevant SRs. We aim to synthesize the
existing evidence on the use of nonpharmacologic, non-
herbal interventions to manage bothersome VMS in
perimenopausal and postmenopausal women. Our find-
ings will help clinicians and women experiencing im-
paired quality of life from VMS to identify potentially
effective nonpharmacological treatments as well as
quantify the effect of such options. If possible, we hope
to provide additional clarity on differential effects of
nonpharmacologic treatments among those with and
without breast cancer and those who underwent natural
versus surgical menopause.
Limitations
We acknowledge that there are potentially other effective
nonpharmacologic interventions that may benefit women
who are experiencing bothersome VMS that will not be
included in our review based on our current protocol. The
choice of included interventions was determined by expert
opinion from the field and those of highest relevance to
practice within the VHA. Selected interventions are meant
to reflect currently used and widely available treatments
while keeping the scope of this review feasible. We limited
our search to SRs and RCTs that were in English, which
may have excluded important studies conducted in
different languages. Of note, some SRs may have included
trials that were not published in English.
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